{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:06:22Z","timestamp":1747181182348,"version":"3.40.5"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2,16]]},"abstract":"<jats:p>Pancreatic cancer (PC) is a malignant tumor of the digestive system with a poor prognosis. PC patients with pancreatitis have a worse prognosis. But nobody reported the relationship between inflammation and prognosis in PC. Based on this, we are going to explore inflammation-related prognostic signature to predict patients\u2019 survival and potential therapeutic target. We screened gene expression profile and corresponding clinical information of patients from The Cancer Genome Atlas (TCGA) database. Gene set enrichment analysis (GSEA) was performed to identify differentially expressed genes (DEGs) between tumor and normal tissues with <jats:italic toggle=\"yes\">P<\/jats:italic> value\u2005&lt;\u2005.05. Univariate and multivariate Cox regression analysis was applied to identify possible prognostic inflammation genes and establish an inflammation-related risk score system, which was validated by Kaplan\u2013Meier and Receiver operating characteristic (ROC) curves. Finally, we used the TISIDB database to predict targeted drugs for up-regulated gene hepatocyte growth factor receptor (MET) and used AUTODOCK software for molecular docking. We built a prognostic model consisted of 3 inflammation-related genes (tumor necrosis factor receptor associated factor 1\/TFAR1, tyrosine kinase 2\/TYK2, MET). According to the median value of those genes\u2019 risk score, PC patients were ranked into high- (88) and low-risk (89) groups. Then, the results of the Kaplan\u2013Meier curves and the area under the curve (AUC) of the ROC curves showed this model had a good predictive power (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.001, AUC\u2005=\u20050.806). The result of human protein atlas (HPA) database showed the expression of TRAF1 and TYK2 were low in pancreatic cancer, the expression of MET was high. TISIDB database founded brigatinib could target to MET. And AUTODOCK showed brigatinib had a nice docking with MET. Taken together, our study suggested that inflammation-associated prognostic signature might be used as novel biomarkers for predicting prognosis in PC patients and potential therapeutic target of the disease.<\/jats:p>","DOI":"10.1097\/md.0000000000036932","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T19:06:44Z","timestamp":1708110404000},"page":"e36932","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Identify novel inflammation-related prognostic signature in pancreatic cancer patients"],"prefix":"10.1097","volume":"103","author":[{"given":"Yuan","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, the First Hospital of China Medical University, Shenyang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoying","family":"Zhang","sequence":"additional","affiliation":[{"name":"Central Sterile Supply Department, the First Hospital of China Medical University, Shenyang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7770-0662","authenticated-orcid":false,"given":"Haiyan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, the First Hospital of China Medical University, Shenyang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/jjco\/hyq011","article-title":"Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506.","volume":"40","author":"Ishii","year":"2010","journal-title":"Jpn J Clin Oncol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020.","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"16022","DOI":"10.1038\/nrdp.2016.22","article-title":"Pancreatic cancer.","volume":"2","author":"Kleeff","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/MOG.0b013e328363affe","article-title":"Deciphering the role of stroma in pancreatic cancer.","volume":"29","author":"Waghray","year":"2013","journal-title":"Curr Opin Gastroenterol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1097\/01.sla.0000128681.76786.07","article-title":"Inflammatory mechanisms contributing to pancreatic cancer development.","volume":"239","author":"Farrow","year":"2004","journal-title":"Ann Surg"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"G315","DOI":"10.1152\/ajpgi.00115.2004","article-title":"Inflammation and cancer V. Chronic pancreatitis and pancreatic cancer.","volume":"287","author":"Whitcomb","year":"2004","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.cell.2011.11.025","article-title":"EMT and dissemination precede pancreatic tumor formation.","volume":"148","author":"Rhim","year":"2012","journal-title":"Cell"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","article-title":"Molecular signatures database (MSigDB) 3.0.","volume":"27","author":"Liberzon","year":"2011","journal-title":"Bioinformatics"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.0006-341X.2000.00337.x","article-title":"Time-dependent ROC curves for censored survival data and a diagnostic marker.","volume":"56","author":"Heagerty","year":"2000","journal-title":"Biometrics"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1093\/bioinformatics\/btz210","article-title":"TISIDB: an integrated repository portal for tumor-immune system interactions.","volume":"35","author":"Ru","year":"2019","journal-title":"Bioinformatics"},{"key":"R13-20250504","first-page":"453","article-title":"Patient samples of renal cell carcinoma show reduced expression of TRAF1 compared with normal kidney and functional studies in vitro indicate TRAF1 promotes apoptosis: potential for targeted therapy.","volume":"44","author":"Rajandram","year":"2012","journal-title":"Pathology (Phila)"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/01.jnen.0000248553.45456.96","article-title":"Transcriptional profiling of the nuclear factor-kappaB pathway identifies a subgroup of primary lymphoma of the central nervous system with low BCL10 expression.","volume":"66","author":"Courts","year":"2007","journal-title":"J Neuropathol Exp Neurol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.21037\/atm-20-6112","article-title":"Development and validation of a prognostic and immunotherapeutically relevant model in hepatocellular carcinoma.","volume":"8","author":"Wang","year":"2020","journal-title":"Ann Transl Med"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2147\/JIR.S284889","article-title":"Identification of prognostic biomarkers and molecular targets among JAK family in breast cancer.","volume":"14","author":"Liu","year":"2021","journal-title":"J Inflamm Res"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1158\/1078-0432.CCR-13-2173","article-title":"MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array.","volume":"20","author":"Albiges","year":"2014","journal-title":"Clin Cancer Res"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1002\/cam4.3834","article-title":"MET transcriptional regulator\/serine peptidase inhibitor kunitz type 1 panel operating through HGF\/c-MET axis as a prognostic signature in pan-cancer.","volume":"10","author":"Xiang","year":"2021","journal-title":"Cancer Med"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"v56","DOI":"10.1093\/annonc\/mdv295","article-title":"Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.","volume":"26","author":"Ducreux","year":"2015","journal-title":"Ann Oncol"},{"key":"R20-20250504","first-page":"418","article-title":"Neoadjuvant therapy for localized pancreatic cancer: guiding principles.","volume":"6","author":"Fathi","year":"2015","journal-title":"J Gastrointest Oncol"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1007\/s10637-021-01095-5","article-title":"Effect of severe renal impairment on the pharmacokinetics of brigatinib.","volume":"39","author":"Gupta","year":"2021","journal-title":"Invest New Drugs"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jtho.2020.11.023","article-title":"Brigatinib after progression from alectinib or crizotinib: paving the way for treatment sequencing of ALK Inhibitors in ALK-positive NSCLC.","volume":"16","author":"Song","year":"2021","journal-title":"J Thorac Oncol"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s40265-020-01449-y","article-title":"Brigatinib: a review in ALK-inhibitor naive advanced ALK-positive NSCLC.","volume":"81","author":"Hoy","year":"2021","journal-title":"Drugs"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000036932","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T03:18:06Z","timestamp":1746328686000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000036932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,16]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000036932","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2024,2,16]]}}}